Is Rosiglitazone use associated with an increase in intensive eye treatment in diabetic patients? A community based study

Shani, Michal; Feldman, Leonid; Kaiserman, Igor; Dresner, Julian; Baevsky, Tuvia; Vinker, Shlomo

doi:10.3109/13814788.2011.590191

Cited by 2 publications

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…• Sitagliptin may delay or prevent DR by preventing nitrosative (reactive nitrogen and oxygen species) stress, inflammation and apoptosis in retinal cells, and preventing increase in BRB permeability [18,19] • Vildagliptin significantly inhibited increase in body weight and decreased average fasting glucose in rats, and inhibited inflammatory and thrombogenic reactions in the retinas of • Rosiglitazone use associated with increased rates of laser treatment and vitrectomy [46] Experimental research…”

Section: Relationship With Retinopathymentioning

confidence: 99%

“…A longitudinal medical record review found 59% relative risk reduction in progression to PDR over 3 years and lower rates of visual acuity loss with rosiglitazone [45]. A community-based study of 1304 patients on rosiglitazone vs 5385 control patients found rosiglitazone use was associated with increased rates of laser treatment and vitrectomy after a median 3.6 years follow-up [46]. Finally, a 16-week prospective randomised control study of 50 patients assigned to rosiglitazone, pioglitazone or control found TZD use was associated with decreased mediators of endothelial dysfunction, reduced markers of inflammation but increased markers of angiogenic activity, which could be of concern in PDR [47].…”

Section: Thiazolidinedionesmentioning

confidence: 99%

See 1 more Smart Citation

New anti-hyperglycaemic agents for type 2 diabetes and their effects on diabetic retinopathy

Saw

Wong

et al. 2019

Eye

View full text Add to dashboard Cite

There has been an increase in the range of non-insulin anti-hyperglycaemic agents used to treat type 2 diabetes. With the globally rising rates of type 2 diabetes and complications such as diabetic retinopathy, it is important for ophthalmologists to be aware of these new agents and their impacts on diabetic retinopathy and diabetic macular oedema. We conducted a review of the literature to determine if there were any beneficial or harmful effects of the currently used anti-hyperglycaemic agents on diabetic retinopathy or diabetic macular oedema. Our review of the current literature found that apart from thiazolidinediones, anti-hyperglycaemic agents have been reported to have beneficial or neutral effects on diabetic eye complications. Thiazolidinediones (pioglitazone is the only one currently available) have been linked to incident or worsening diabetic macular oedema, although the rate is believed to be low. Glucagon-like peptide 1 (GLP1) agonists (incretins) in general are beneficial except semaglutide which is associated with increased rates of diabetic retinopathy complications. These results have implications for selection of anti-hyperglycaemic agents for patients with diabetic retinopathy or macular oedema. Further studies need to be conducted to identify if reported beneficial effects are independent of the impact of glycaemic control. Early worsening of retinopathy with tight glycaemic control should also be noted in interpretation of future studies.

show abstract

Section: Relationship With Retinopathymentioning

confidence: 99%